UCLA engineers and scientists have engineered a type of synthetic protein—a chimeric antigen receptor, or CAR, that responds to soluble protein targets. The advance shows great promise for helping the body’s immune system seek out and destroy cancer because it could boost the effectiveness of immunotherapies against solid tumors that are otherwise highly resistant to the body’s immune response.